Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of Praxis Precision Medicines, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001689548.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- PRAX on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001689548
- Issuer location
- Boston, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Praxis Precision Medicines, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 12%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 12%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
12%
FMR LLC
7.7%
PERCEPTIVE ADVISORS LLC
7.2%
BAKER BROS. ADVISORS LP
6.3%
ORBIS INVESTMENT MANAGEMENT LTD
5.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
12%
|
$146,484,527
2,763,859 shares
|
+$12,214,062 | 30 Sep 2025 |
| FMR LLC |
13F
13D/G
Company
|
7.7%
from 13D/G
|
$775,677,279
2,316,907 shares
|
— | 30 Jun 2026 |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
Company
|
7.2%
from 13D/G
|
$681,627,753
2,035,986 shares
|
— | 30 Jun 2026 |
| BAKER BROS. ADVISORS LP |
13F
13D/G
Company
|
6.3%
from 13D/G
|
$586,953,158
1,753,198 shares
|
— | 30 Jun 2026 |
| ORBIS INVESTMENT MANAGEMENT LTD |
13D/G
|
5.5%
|
$494,567,986
1,526,680 shares
|
-$305,074,405 | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.1%
|
$457,291,677
1,419,323 shares
|
$0 | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
4.9%
|
$37,813,688
1,016,497 shares
|
-$6,466,960 | 31 Mar 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
4.8%
from 13D/G
|
$315,707,000
942,999 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$22,122,289.
Buys
$33,198,124
Insiders: 1
Sells
$11,075,834
Insiders: 3
Net
+$22,122,289
Shares: +263,580
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 313,910
Shares: 50,330
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 11,600 | $0 | $3,611,335 | -$3,611,335 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 313,910 | 38,730 | $33,198,124 | $7,464,499 | +$25,733,624 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Praxis Precision Medicines, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Adage Capital Management, L.P.
Net 12M change
+$22,122,289
Latest report
08 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Adage Capital Management, L.P. | 10%+ Owner | $288,424,500 | +$33,198,124 | +13% | Filing P/S | 16 Oct 2025 |
| Clarus Lifesciences III, L.P. | 10%+ Owner | $123,282,606 | Mixed | 12 May 2021 | ||
| Marcio Souza | Chief Executive Officer, Director | $18,925,825 | Mixed | 08 Jul 2026 | ||
| Timothy Edwin Kelly | Chief Financial Officer | $10,041,695 | Mixed | 14 May 2026 | ||
| Megan Sniecinski | Chief Operating Officer | $9,235,254 | Mixed | 14 May 2026 | ||
| Alex Nemiroff | General Counsel and Secretary | $8,380,376 | -$4,852,256 | -37% | Mixed | 14 May 2026 |
| Dean J. Mitchell | Director | $5,999,822 | Mixed | 10 Jun 2026 | ||
| Lauren Mastrocola | Principal Accounting Officer | $4,372,974 | -$2,612,244 | -37% | Mixed | 14 May 2026 |
| William D. Young | Director | $1,053,239 | Mixed | 10 Jun 2026 | ||
| Nicole Sweeny | Chief Commercial Officer | $972,813 | Mixed | 12 Feb 2023 | ||
| Jeffrey B. Kindler | Director | $817,396 | Mixed | 10 Jun 2026 | ||
| Stuart A. Arbuckle | Director | $817,396 | Mixed | 10 Jun 2026 | ||
| Jill DeSimone | Director | $737,802 | -$3,611,335 | -83% | Filing P/S | 24 Jun 2026 |
| Gregory Norden | Director | $502,294 | Mixed | 10 Jun 2026 | ||
| Jeffrey Chodakewitz | Director | $441,722 | Mixed | 10 Jun 2026 | ||
| Merit Ester Cudkowicz | Director | $441,722 | Mixed | 10 Jun 2026 | ||
| BSOF Parallel Master Fund L.P. | 10%+ Owner | $0 | Mixed | 06 Oct 2021 | ||
| Bernard Ravina | Chief Medical Officer | Mixed | 22 Jun 2022 | |||
| Stefan Vitorovic | Director | Mixed | 26 May 2022 |
Recent insider transactions for Praxis Precision Medicines, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Marcio Souza | PRAX | Common Stock | Gift | -100% | -2,600 | 0 | 08 Jul 2026 | Held by spouse | ||
| Marcio Souza | PRAX | Common Stock | Gift | -26.6% | -20,521 | 56,495 | 08 Jul 2026 | Direct | ||
| Jill DeSimone | PRAX | Common Stock | Sale | -83.2% | $3,611,335 | $311.32 | -11,600 | 2,337 | 24 Jun 2026 | Direct |
| Jill DeSimone | PRAX | Common Stock | Options Exercise | 496.4% | 11,600 | 13,937 | 24 Jun 2026 | Direct | ||
| Jill DeSimone | PRAX | Stock Option (Right to Buy) | Options Exercise | -100% | -11,600 | 0 | 24 Jun 2026 | Direct | ||
| Stuart A. Arbuckle | PRAX | Common Stock | Award | 117.6% | 1,371 | 2,537 | 10 Jun 2026 | Direct | ||
| Stuart A. Arbuckle | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Jeffrey Chodakewitz | PRAX | Common Stock | Award | 1,371 | 1,371 | 10 Jun 2026 | Direct | |||
| Jeffrey Chodakewitz | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| William D. Young | PRAX | Common Stock | Award | 72.2% | 1,371 | 3,269 | 10 Jun 2026 | Direct | ||
| William D. Young | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Jill DeSimone | PRAX | Common Stock | Award | 141.9% | 1,371 | 2,337 | 10 Jun 2026 | Direct | ||
| Jill DeSimone | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Merit Ester Cudkowicz | PRAX | Common Stock | Award | 1,371 | 1,371 | 10 Jun 2026 | Direct | |||
| Merit Ester Cudkowicz | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Dean J. Mitchell | PRAX | Common Stock | Award | 7.95% | 1,371 | 18,622 | 10 Jun 2026 | Direct | ||
| Dean J. Mitchell | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Jeffrey B. Kindler | PRAX | Common Stock | Award | 117.6% | 1,371 | 2,537 | 10 Jun 2026 | Direct | ||
| Jeffrey B. Kindler | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Gregory Norden | PRAX | Common Stock | Award | 729.3% | 1,371 | 1,559 | 10 Jun 2026 | Direct | ||
| Gregory Norden | PRAX | Stock Option (Right to Buy) | Award | 648 | 648 | 10 Jun 2026 | Direct | |||
| Lauren Mastrocola | PRAX | Common Stock | Award | 0.94% | 127 | 13,573 | 14 May 2026 | Direct | ||
| Alex Nemiroff | PRAX | Common Stock | Award | 0.3% | 78 | 26,011 | 14 May 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Award | 0.39% | 121 | 31,167 | 14 May 2026 | Direct | ||
| Megan Sniecinski | PRAX | Common Stock | Award | 0.31% | 89 | 28,664 | 14 May 2026 | Direct | ||
| Marcio Souza | PRAX | Common Stock | Award | 0.16% | 126 | 77,016 | 14 May 2026 | Direct | ||
| Stuart A. Arbuckle | PRAX | Common Stock | Award | 1,166 | 1,166 | 06 Feb 2026 | Direct | |||
| Stuart A. Arbuckle | PRAX | Stock Option (Right to Buy) | Award | 224 | 224 | 06 Feb 2026 | Direct | |||
| Jeffrey B. Kindler | PRAX | Common Stock | Award | 1,166 | 1,166 | 06 Feb 2026 | Direct | |||
| Jeffrey B. Kindler | PRAX | Stock Option (Right to Buy) | Award | 224 | 224 | 06 Feb 2026 | Direct | |||
| Lauren Mastrocola | PRAX | Common Stock | Tax liability | -2.49% | -344 | 13,446 | 12 Jan 2026 | Direct | ||
| Megan Sniecinski | PRAX | Common Stock | Tax liability | -3.01% | -885 | 28,530 | 12 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Common Stock | Tax liability | -2.88% | -768 | 25,933 | 12 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Tax liability | -2.95% | -943 | 31,046 | 12 Jan 2026 | Direct | ||
| Lauren Mastrocola | PRAX | Common Stock | Tax liability | -2.59% | -367 | 13,790 | 10 Jan 2026 | Direct | ||
| Megan Sniecinski | PRAX | Common Stock | Tax liability | -3.56% | -1,087 | 29,415 | 10 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Common Stock | Tax liability | -3.32% | -917 | 26,701 | 10 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Common Stock | Tax liability | -4.01% | -1,335 | 31,989 | 10 Jan 2026 | Direct | ||
| Marcio Souza | PRAX | Common Stock | Tax liability | -5.24% | -4,252 | 76,890 | 10 Jan 2026 | Direct | ||
| Lauren Mastrocola | PRAX | Common Stock | Award | 36% | 3,750 | 14,157 | 08 Jan 2026 | Direct | ||
| Lauren Mastrocola | PRAX | Stock Option (Right to Buy) | Award | 7,500 | 7,500 | 08 Jan 2026 | Direct | |||
| Megan Sniecinski | PRAX | Common Stock | Award | 46.1% | 9,625 | 30,502 | 08 Jan 2026 | Direct | ||
| Megan Sniecinski | PRAX | Stock Option (Right to Buy) | Award | 7,700 | 7,700 | 08 Jan 2026 | Direct | |||
| Alex Nemiroff | PRAX | Common Stock | Award | 33.1% | 6,875 | 27,618 | 08 Jan 2026 | Direct | ||
| Alex Nemiroff | PRAX | Stock Option (Right to Buy) | Award | 5,500 | 5,500 | 08 Jan 2026 | Direct | |||
| Timothy Edwin Kelly | PRAX | Common Stock | Award | 35.9% | 8,800 | 33,324 | 08 Jan 2026 | Direct | ||
| Timothy Edwin Kelly | PRAX | Stock Option (Right to Buy) | Award | 7,040 | 7,040 | 08 Jan 2026 | Direct | |||
| Marcio Souza | PRAX | Common Stock | Award | 51.7% | 27,640 | 81,142 | 08 Jan 2026 | Direct | ||
| Marcio Souza | PRAX | Stock Option (Right to Buy) | Award | 22,110 | 22,110 | 08 Jan 2026 | Direct | |||
| Lauren Mastrocola | PRAX | Common Stock | Tax liability | -0.34% | -35 | 10,407 | 07 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.